Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
MHLW to Take Strict Action on Xarelto Side Effect Case: Minister
Health Minister Yasuhisa Shiozaki said on May 30 that his ministry will “take strict action” on Bayer Yakuhin, including possibly imposing an administrative penalty, over its failure to appropriately report side effects associated with its major anticoagulant Xarelto (rivaroxaban). Speaking…
To read the full story
Related Article
- Employee Sues Bayer Japan for Emotional Distress over Xarelto Scandal
March 19, 2019
- JPMA Reprimands Bayer over Side Effect Reporting Violation, Chides “Inappropriate” Promotion
October 20, 2017
- (Update) Bayer Told to Improve Practice over ADR Reporting Delays, Gets “Verbal Guidance” for Xarelto Survey Fuss
October 2, 2017
- Bayer Instruction Existed in Patient Info Acquisition, Sales Rep Tells Govt Panel
August 25, 2017
- Whistleblower Bayer Rep Raps “No Instruction” Finding in Xarelto Scandal Probe
July 21, 2017
- Probe Finds No HQ Instruction for Improper Patient Info Acquisition in Xarelto Surveys, Bayer Execs Take 3-Month Pay Cuts
July 18, 2017
- MHLW Orders Bayer Blanket Probe on Side Effect Reporting
May 30, 2017
- Bayer Fails to Report 12 Side Effect Cases for Xarelto, Scandal Probe Finds
May 29, 2017
REGULATORY
- Japan to Delist 387 Drugs from NHI Price List, Including Renivace
February 16, 2026
- Chuikyo Payers Signal Mixed Views on Off-Year Drug Price Revisions
February 16, 2026
- Chuikyo Issues FY2026 Fee Revision Recommendation, Creates New Premiums for Generics and Biosimilars
February 16, 2026
- Japan Panel to Review Sumitomo, Cuorips iPSC Products on Feb. 19
February 16, 2026
- Update: DMD Gene Therapy Elevidys Cleared for NHI Listing at 305 Million Yen
February 13, 2026
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…